21 C.F.R. § 349.55
Labeling of ophthalmic astringent drug products.
Cite as 21 C.F.R. § 349.55 (2026)
(a)
Statement of identity.
The labeling of the product contains the established name of the drug, if any, and identifies the product as an “astringent” (select one of the following: “eye” or “ophthalmic”) “(insert dosage form, e.g., drops).”
(b)
Indications.
The labeling of the product states, under the heading “Indications,” the following phrase: “For the temporary relief of discomfort from minor eye irritations.”
(c)
Warnings.
In addition to the warnings in § 349.50, the labeling of the product contains the following warnings under the heading “Warnings” for products containing any ingredient identified in § 349.10:
(1) “If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.”
(2) “If solution changes color or becomes cloudy, do not use.”
(d)
Directions.
The labeling of the product contains the following information under the heading “Directions”: Instill 1 to 2 drops in the affected eye(s) up to four times daily.
- Cross-references to the CFR
- 349.10349.50